Arkolith/Insider Trading/PRLD/Form 4

Orbimed Capital LLC

Director, 10% OwnerPrelude Therapeutics Inc (PRLD) · full profile →Form 4 · filed May 24, 2023
Net Buying
Open-Market Buys
$5.0M
Open-Market Sells
$0
Net Open-Market Flow
$5.0M
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 22, 2023Buy(P)870K$5.75$5.0M10.1M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000947871-23-000628) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML